| Literature DB >> 17011782 |
Daniel P Walker1, Donn G Wishka, David W Piotrowski, Shaojuan Jia, Steven C Reitz, Karen M Yates, Jason K Myers, Tatiana N Vetman, Brandon J Margolis, E Jon Jacobsen, Brad A Acker, Vincent E Groppi, Mark L Wolfe, Bruce A Thornburgh, Paula M Tinholt, Luz A Cortes-Burgos, Rodney R Walters, Matthew R Hester, Eric P Seest, Lester A Dolak, Fusen Han, Barbara A Olson, Laura Fitzgerald, Brian A Staton, Thomas J Raub, Mihaly Hajos, William E Hoffmann, Kai S Li, Nicole R Higdon, Theron M Wall, Raymond S Hurst, Erik H F Wong, Bruce N Rogers.
Abstract
A novel set of azabicyclic aryl amides have been identified as potent and selective agonists of the alpha7 nAChR. A two-pronged approach was taken to improve the potential hERG liability of previously disclosed alpha7 nAChR agonist, PNU-282,987, while maintaining the compound's other desirable pharmacological properties. The first approach involved further exploration of the aryl carboxylic acid fragment of PNU-282,987, while the second approach focused on modification of the azabicyclic amine portion of PNU-282,987. The best compounds from each series are characterized by rapid brain penetration, good oral bioavailability in rat, and demonstrate in vivo efficacy in a rat P50 auditory sensory gating assay. At least one analog from each series (1h, 1o, 2a, 9a, and 18a) shows an improved hERG safety profile over PNU-282,987.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17011782 DOI： 10.1016/j.bmc.2006.09.019
Source DB: PubMed Journal: Bioorg Med Chem ISSN： 0968-0896 Impact factor: 3.641